first glp 1 agonist GLP-1 use tripled among non-diabetics, reaching $5.8B in 2022 GLP-1 | Summary

While these agents are not recommended during pregnancy, their use in the preconception, periconception, and postpartum periods is increasing

What to know about the obesity-breast cancer link

A randomized, phase 3, open-label trial comparing the effect of the addition of tirzepatide once weekly versus insulin lispro (U100) three times daily in participants with type 2 diabetes inadequately controlled on insulin glargine (U100) with or without metformin (SURPASS-6)

Faster weight loss means shorter treatment duration to reach a target, lower total compound consumption, and earlier access to the metabolic health benefits that accompany weight reduction

In the LEAD series of studies, clinical data demonstrated that treatment with liraglutide for 26 weeks can reduce SBP [4]

Obesity is a multi-faceted disease and vitamin D supplementation may be advantageous with GLP-1RA treatment, especially to address potentially deficient serum 25(OH)D levels